Marion Webb
Managing Editor at Medtech Insight
Managing Editor, Citeline, dog mom, runner, recovering triathlete. All views are my own. #medtech #digitalhealth #robotics #AI #ML #femtech #womenshealth
Articles
-
2 days ago |
insights.citeline.com | Marion Webb |Shubham Singh |Nancy Pham
Medtech Giants Brace for Tariffs Impact: Responses Range From Financial To Philosophical Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.
-
3 days ago |
insights.citeline.com | Marion Webb |Brian Bossetta |Natasha Barrow |Elizabeth Orr
Digital Health Roundup: Synchron Syncs With Apple, Ketryx’s AI Agents, AdvaMed’s AI RoadMapIn this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.
-
5 days ago |
insights.citeline.com | Marion Webb
Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement SystemAbbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery. Abbott's Tendyne transcatheter mitral valve system • Source: Abbott Laboratories
-
1 week ago |
insights.citeline.com | Marion Webb
Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.
Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials 2
1 week ago |
insights.citeline.com | Marion Webb
Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials 2Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 3K
- DMs Open
- No
Consumer Healthtech Investment Totaled $4.5BN In 2024, But Bar Is High Amid Economic Uncertainty https://t.co/GKglUtLH2n @Medtech_Insight @IrmaRaste @EvanKirstel #consumer #healthtec #AI #digitalhealth
Subsense Develops Nonsurgical, Nanoparticle-Based Computer Interface For Neurological Disorders https://t.co/5785P2Uj0v #neurology @Citeline @Medtech_Insight @IrmaRaste @EvanKirstel #AI #digitalhealth
No Knife, No Burn, Just Bubbles: HistoSonics Hits 90% Tumor Control In #HOPE4Liver Trial, Eyes IPO Timing https://t.co/WSoCdaLMS4 @Medtech_Insight @Citeline #medtech #cancer #oncology @IrmaRaste @EvanKirstel